Related Experiment Video

Updated: Jun 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment of special populations with chronic hepatitis B infection

Irene N Rapti1, Stephanos J Hadziyannis

  • 1Department of Medicine & Liver Unit, Henry Dunant Hospital, Athens, Greece.

Expert Review of Gastroenterology & Hepatology
|June 10, 2011
PubMed

Insights

This review discusses chronic hepatitis B treatments for special patient groups often excluded from clinical trials. It highlights the importance of tailored therapies for coinfections, transplant recipients, and other vulnerable populations.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Standard chronic hepatitis B treatments are approved based on trials excluding complex patient groups.
  • Excluded groups include those with decompensated cirrhosis, comorbidities, or contraindications.
  • These special populations represent a significant percentage of chronic hepatitis B patients.

Purpose of the Study:

  • To review and discuss treatment strategies for chronic hepatitis B in special patient categories.
  • To emphasize the critical need for effective therapies in these often-excluded groups.

Main Methods:

  • Literature review of existing therapeutic agents and clinical trial data.
  • Analysis of treatment considerations for specific patient subgroups.
  • Discussion of challenges and recommendations for managing chronic hepatitis B in complex cases.

Main Results:

  • Identified key patient groups requiring specialized chronic hepatitis B management, including those with coinfections (hepatitis D, C, HIV), post-transplant/immunosuppressed patients, those with end-stage renal disease, acute/fulminant hepatitis B, children, and pregnant women.
  • Highlighted that treatment for these groups is often more critical than for standard patients.
  • Emphasized that these special populations constitute a substantial proportion of chronic hepatitis B virus infection cases in real-world settings.

Conclusions:

  • Effective management of chronic hepatitis B in special populations is crucial due to their unique clinical needs and significant prevalence.
  • Tailored therapeutic approaches are necessary to address the complexities of treating chronic hepatitis B in these diverse patient groups.
  • Further research and clinical guidelines are needed to optimize treatment outcomes for these vulnerable individuals.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...